Generic Version

Type: Keyphrase
Name: Generic Version
First reported 16 hours ago - Updated 9 hours ago - 1 reports

AIDS 2014: Activists launch protest against Gilead VP

Activists at the 20th international AIDS conference launched a protest against pharmaceutical giant Gilead, producers of a new Hepatitis C drug, Sovaldi.The activists who are protesting against the exorbitant cost of Sovaldi (sofosbuvir), a Hepatitis ... [Published Gay News Network - 16 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

FDA reviewing what could be first biosimilar drug

The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug. ... [Published Crawford Financial Planning - 10 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

INTAS ROLLS OUT CHEAP CANCER DRUG

Intas Pharmaceuticals has rolled out cheap cancer drug, which is a generic version of blood cancer drug Azadine. The price of the drug launched by Intas is at one-fifth of the price of the currently available drug. ... [Published Pharmacy Choice - 16 hours ago]
First reported Jul 23 2014 - Updated 23 hours ago - 1 reports

Weak lung drug sales and strong pound hit GlaxoSmithKline

LONDON, July 23 (Reuters) - GlaxoSmithKline's sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.A run of weak quarters highlights ... [Published CNBC - Jul 23 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

2-year probation for ex-radio host

Curtice man receives intervention for drugsA former radio host and newspaper columnist who was arrested with drugs and a loaded handgun last year was granted intervention instead of a felony conviction Wednesday.Troy Neff, 46, of Curtice, Ohio, pleaded ... [Published Toledoblade.com - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Court Prohibits GSK From Providing Generic Paxil to Mylan’s Competitor

Mylan has further cemented its win in a breach-of-contract lawsuit against GlaxoSmithKline with a court order prohibiting GSK from providing an authorized generic version of the antidepressant Paxil to Mylan’s competitor Apotex.The U.S. District Court ... [Published FDA News - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Cubist strikes agreement with competitor to delay generic Cubicin

A competitor of antibiotics maker Cubist Pharmaceuticals has agreed not to launch a generic version of its flagship drug for skin infections until at least Dec. 1 while a judge decides on a patent challenge.In 2012, Illinois-based Hospira indicated it ... [Published Boston Business Journal - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook.The company announced at midday that it ... [Published BullBearings - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

GSK's second quarter revenue hurt by drug rivals

LONDON (ShareCast) - - Turnover falls 4%- Competition from generic brands hurts profit- Full-year 2014 guidance cutGlaxoSmithKline (GSK) on Wednesday slashed its 2014 outlook as it reported a 4% fall in second quarter revenue to £5.6bn.The drugmaker, ... [Published Sharewatch Global Market - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

How Teva Pharmaceutical Is Attacking the Generics to Defend Its Turf

NEW YORK (TheStreet) -- Teva Pharmaceutical's ADR continues to benefit from the delay in FDA approval of a generic version of its top-selling multiple sclerosis drug Copaxone. The approval delay has given Teva more time to switch patients to a new, three-times-per-week ... [Published West Hartford News - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Glenmark Generics receives ANDA approval

Telmisartan is Glenmark’s generic version of Boehringer Ingelheim’s MicardisGlenmark Generics has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (US FDA) for Telmisartan Tablets.Glenmark will ... [Published Express Pharma - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Sandoz unveils generic version of cystic fibrosis medication in US

Sandoz has announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI, currently marketed by Novartis Pharmaceuticals Corporation. Tobramycin inhalation solution, USP is indicated for the management ... [Published Individual.com - Jul 21 2014]

Quotes

If their advisor tells them their portfolio is up say 7% this year, they'll come back with something like "Yeah, but if such-and-such investment hadn't tanked, I'd be up 10%."
Zacks’ analyst wrote, "Novo Nordisk reported first-quarter 2014 earnings of $0.45 per ADR, a penny above the Zacks Consensus Estimate of $0.44. Though revenues of $3.7 billion missed the Zacks Consensus Estimate of $3.85 billion, Levemir, modern insulins and Victoza recorded good sales. The recruitment in the cardiovascular outcomes study protocol for Tresiba is progressing ahead of plans. However, the loss of reimbursement with a large pharmacy benefit manager and unexpected changes in the wholesaler stock level in the U S is disappointing. The recent entry of Mylan’s generic version of Prandin has also affected sales. Thus, the company now expects sales to grow 7-10% below the earlier outlook of 8-11%. Hence, we maintain a Neutral recommendation on Novo Nordisk."
"We expect the transition of this portfolio to continue over the next 2-3 years and remain confident that GSK will maintain its leadership position in respiratory well into the next decade" he said
"The ongoing investigation in China adversely impacted emerging markets pharmaceuticals and vaccines sales growth by an estimated four percentage points" the group said in its interim statement on Wednesday

More Content

All (714) | News (573) | Reports (0) | Blogs (134) | Audio/Video (0) | Fact Sheets (0) | Press Releases (7)
sort by: Date | Relevance
Pfizer's Incoming Patent Cliff [Published Motley Fool - 9 hours ago]
FDA reviewing what could be first biosimilar drug [Published Crawford Financial Planning - 10 hours ago]
Is This The Best Health Care Stock To Own Right... [Published StreetAuthority - 15 hours ago]
AIDS 2014: Activists launch protest against Gil... [Published Gay News Network - 16 hours ago]
INTAS ROLLS OUT CHEAP CANCER DRUG [Published Pharmacy Choice - 16 hours ago]
33 tips to help you save hundreds on your groce... [Published Philly.com - 17 hours ago]
Is Teva Pharmaceuticals Stock Really Your Best ... [Published Motley Fool - 17 hours ago]
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y [Published Yahoo! Finance - 18 hours ago]
2-year probation for ex-radio host [Published Toledoblade.com - Jul 24 2014]
United States : LANNETT agrees with SYMPLMED fo... [Published Pharmacy Choice - Jul 24 2014]
Apples New Stickers Ad Is a Treat For Mac Lovers [Published Bidness Etc - Jul 24 2014]
Court Prohibits GSK From Providing Generic Paxi... [Published FDA News - Jul 23 2014]
Zacks Reiterates “Neutral” Rating for Novo Nord... [Published American Banking News - Jul 23 2014]
Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc. [Published JD Supra - Jul 23 2014]
Mylan granted restraining order against Apotex [Published Drug Store News - Jul 23 2014]
Another major drop in sales for GSK [Published Pharmafocus - Jul 23 2014]
Cubist strikes agreement with competitor to del... [Published Boston Business Journal - Jul 23 2014]
Sector movers: Weak results, outlook from Glaxo... [Published BullBearings - Jul 23 2014]
UPDATE 2-GSK warns on profits as weak lung drug... [Published CNBC - Jul 23 2014]
GSK's second quarter revenue hurt by drug rivals [Published Sharewatch Global Market - Jul 23 2014]
Weak lung drug sales and strong pound hit Glaxo... [Published CNBC - Jul 23 2014]
How Teva Pharmaceutical Is Attacking the Generi... [Published West Hartford News - Jul 23 2014]
Health Insurance: A Simplified Guide Anyone Can... [Published Examiner.com - Jul 22 2014]
AptarGroup's (ATR) CEO Stephen Hagge on Q2 2014... [Published Seeking Alpha - Jul 22 2014]
Glenmark Generics receives ANDA approval [Published Express Pharma - Jul 22 2014]
Mylan receives motion for permanent injunction ... [Published PredictWallStreet - Jul 22 2014]
Depomed Reports District Court Order in ANDA Li... [Published Individual.com - Jul 22 2014]
Plan to cut €10m from health spend with GMS sch... [Published Irish Times - Jul 22 2014]
Lannett to distribute Aceon authorized generic [Published Chain Drug Review - Jul 21 2014]
Huawei Ascend P7 - New Huawei Flagship 4G Smart... [Published Prlog - Jul 21 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Lannett inks deal with Symplmed for US distribu... [Published PBR - News - Jul 21 2014]
US-based Lannett has signed an agreement with Symplmed Pharmaceuticals to be the exclusive distributor in the US of an authorized generic version of ACEON (perindopril erbumine tablets) in 2mg, 4mg and 8mg dosage strengths. ...
Innovator Liability at 100 [Published Drug and Device Law - Jul 18 2014]
This post is only from the Reed Smith (more properly, the non-Dechert) side of the blog.One hundred what, you say?Certainly not years; the awful Conte v. Wyeth, Inc., 85 Cal. Rptr.3d 299, (Cal. App. 2008), decision just turned six – this blog is older ...
Lannett Signs Agreement to Be Exclusive U.S. Di... [Published Business Wire Health News - Jul 18 2014]
PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE: LCI) today announced that it has signed an agreement with Symplmed, Inc. to be the exclusive distributor in the United States of an authorized generic version of ACEON® (perindopril erbumine ...
Mylan Wins Motion to Enjoin GlaxoSmithKline fro... [Published PR Newswire: Financial Services - Jul 17 2014]
PITTSBURGH, July 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK) in relation to Paroxetine CR, ...
Yet Another Petition to FDA Says: “Gimme My 5-Y... [Published FDA Law Blog - Jul 17 2014]
By Kurt R. Karst –Our FDA Citizen Petition Tracker is littered with petitions and petitions for reconsideration submitted to FDA over the past 18 months requesting that the Agency recognize a period of 5-year New Chemical Entity (“NCE”) exclusivity for ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Mylan Wins Motion to Enjoin GlaxoSmithKline fro... [Published Financial Services - Jul 17 2014]
Milan District Court Confirms the Validity of A... [Published Financial Services - Jun 12 2014]
ACETO Subsidiary Rising Pharmaceuticals Launche... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
CorePharma, LLC Announces the Launch of Dextroa... [Published Financial Services - Jun 04 2014]
ACETO Subsidiary, Rising Pharmaceuticals, Has L... [Published GlobeNewswire: Acquisitions News - May 27 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.